This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

HIV disease resulting in other types of non-Hodgkin lymphoma기타 유형의 비호지킨림프종을 유발한 인체면역결핍바이러스병

Contents and key points
ItemDetails
A. Classification codesICD-10: B21.2 (HIV disease resulting in other types of non-Hodgkin lymphoma) | Special Copayment Reduction: V103 (severe intractable disease, 5 years)
B. SynonymsHIV-associated non-Hodgkin lymphoma (other types); AIDS-related NHL; HIV-associated DLBCL; HIV-associated primary effusion lymphoma; HIV-associated plasmablastic lymphoma
C. Adult onsetLikelihood of onset in adulthood: Very high — B21.2 is other non-Hodgkin lymphoma not included in B21.1 (Burkitt lymphoma) and B21.3 (other lymphoid malignancies), and includes diffuse large B-cell lymphoma (DLBCL), primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and others. Most occur in adults (30s-60s).
1. HistorySurge in high-grade NHL reported with the AIDS epidemic in the early 1980s. Included as an AIDS-defining malignancy in 1985. Incidence of DLBCL and PEL decreased greatly after ART.
2. CausesHIV-induced B-cell dysregulation, EBV/HHV-8 co-infection, and chronic immune activation act in combination. DLBCL has an EBV association of about 30-40%; PEL requires HHV-8 + EBV in about 70%.
3. GeneticsDLBCL: BCL6 rearrangement (about 20-30%), BCL2 rearrangement, somatic hypermutation. PEL: characterized by HHV-8 LANA-1 positivity, EBV positivity, and BCL2/BCL6/CD20 negativity. PBL: MYC rearrangement is common.
4. General epidemiologyDLBCL, the most common type of AIDS-related NHL, accounts for about 40% of all AIDS NHL. Incidence has decreased by about 70-80% since ART. PEL occurs in about 3-4% of patients with HIV and appears mainly in MSM.
5. PathophysiologyChronic HIV immune activation → B-cell hyperproliferation → tumorigenesis by EBV/HHV-8 → evasion of immune surveillance. DLBCL is more dependent on CD4 decline, while in PEL the HHV-8 latency proteins directly induce tumorigenesis.
6. SymptomsHigh frequency of extranodal involvement (CNS, gastrointestinal tract, bone marrow). Pleural effusion, ascites, pericardial effusion (PEL), oral and oropharyngeal mass (PBL), B symptoms (fever, night sweats, weight loss). Rapid tumor growth.
7. SignsLymphadenopathy, pleural effusion and ascites (PEL), mass effect (increased intracranial pressure, intestinal obstruction), elevated LDH, cytopenia.
8. ScreeningWhen lymphadenopathy, pleural effusion, or ascites of unknown cause occurs in a patient with HIV, differentiate lymphoma immediately. Regular LDH measurement is recommended.
9. DiagnosisTissue biopsy (morphology, immunophenotype, FISH). PEL: cytology of pleural effusion and ascites + HHV-8 LANA-1 immunostaining. Staging with PET-CT. CSF cell examination.
10. TreatmentDLBCL: R-CHOP or SC-EPOCH-R. PEL: CHOP or EPOCH ± anti-HHV-8 treatment (ganciclovir, etc.). PBL: EPOCH or CODOX-M. Early initiation of ART in all types.
11. PrognosisDLBCL: in the era of ART + R-CHOP, CR rate about 50-70%, 5-year survival rate about 40-60%. PEL: very poor, median survival 3-6 months. PBL: poor, 1-year survival rate about 30-40%.
12. PreventionMaintain CD4 with ART. Evidence for prophylactic treatment of HHV-8 and EBV is insufficient. Early HIV diagnosis and treatment is best.
13. ReferencesCarbone A et al. Br J Haematol 2016 and 9 others

1. History

AIDS-related non-Hodgkin lymphoma (NHL) has been reported since the early AIDS epidemic in 1982-1983. In 1985 the CDC included high-grade NHL as an AIDS-defining disease in persons with HIV. Since then, AIDS-related NHL has come to encompass several histologic types, including diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (classified separately as B21.1), primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and primary central nervous system lymphoma (PCNSL). The B21.2 code collectively refers to other types of non-Hodgkin lymphoma not included in B21.1 (Burkitt lymphoma) and B21.3 (other lymphoreticuloendothelial tissue neoplasms).

DLBCL is the most common type of AIDS-related NHL and increased sharply in persons with HIV from the 1980s to the early 1990s. During this period, AIDS-related DLBCL showed a very aggressive course and poor prognosis, and the bone marrow toxicity of chemotherapy acted synergistically with HIV-induced bone marrow dysfunction, so treatment-related mortality was high. After the introduction of ART in 1996, the incidence of DLBCL decreased greatly, and tolerance to chemotherapy also improved in patients with HIV whose immune function had recovered.

Primary effusion lymphoma (PEL) was first described by Cesarman et al. in 1995 as an HHV-8-associated lymphoma. It is a distinctive lymphoma originating in effusions of the pleural, peritoneal, and pericardial cavities, and was established as a new type with an immunophenotype completely different from that of Burkitt lymphoma and DLBCL. Plasmablastic lymphoma (PBL) was first described by Delecluse et al. in 1997 in oral lesions of patients with HIV; it is a B-cell lymphoma with plasma cell differentiation and is characterized by CD20 negativity.

The introduction of rituximab (anti-CD20) in the 2000s greatly improved the treatment of AIDS-related CD20+ DLBCL. R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) combination therapy was established as the standard treatment. At the same time, the safety and efficacy of combining ART with chemotherapy were verified in several clinical trials.


2. Causes

The causes of AIDS-related NHL included in B21.2 differ by type, and the combined action of HIV-induced immunosuppression and specific oncogenic viruses is key.

Diffuse large B-cell lymphoma (DLBCL)

The most common AIDS-related NHL, it occurs against a background of HIV-induced CD4 decline (median about 100-200/μL). The EBV association is about 30-40%, and EBV EBER-positive tumors tend to show a more aggressive course. DLBCL has molecular subtypes including germinal center B-cell type (GCB) and non-germinal center B-cell type (non-GCB, activated B cell-like, ABC), and the non-GCB type is more common in HIV-associated disease.

Primary effusion lymphoma (PEL)

HHV-8 (KSHV) infection is essential, and EBV co-infection accompanies it in about 70%. HHV-8 transforms lymphocytes in the effusion into large B cells that have not differentiated toward plasma cells. It occurs mainly in MSM with HIV infection, and HHV-8 seropositivity is an essential prerequisite.

Plasmablastic lymphoma (PBL)

It occurs mainly in the oral cavity and digestive tract and appears characteristically in patients with HIV infection. The EBV association is about 60-70%, and MYC rearrangement is found in about 50%. The immunophenotype is characterized by CD20 negativity and CD138+, VS38c+, MUM1+, reflecting differentiation toward plasma cells.

Primary central nervous system lymphoma (PCNSL)

The EBV association is very high (about 95%), and nearly all cases in patients with severe immunosuppression (CD4 <50/μL) are EBV-positive. It is the type of AIDS-related NHL whose incidence has decreased the most since the introduction of ART.


3. Genetics

Each NHL type included in B21.2 has distinct genetic characteristics. In DLBCL, BCL6 rearrangement (about 20-30%), BCL2-IgH translocation, and c-MYC rearrangement (in some) are found. In non-GCB DLBCL, NF-κB pathway activation (CD79B, MYD88, CARD11 mutations) and BCL2 amplification are common. In HIV-associated DLBCL, somatic hypermutation is prominent, suggesting a germinal center B-cell origin. In PEL, HHV-8 LANA-1 positivity is the defining finding, and the immunophenotype is distinctive (CD20-, CD79a-, CD45+, CD138±, activation markers CD30+, CD38+). It is characterized by the absence of BCL2/BCL6 rearrangement and by immunoglobulin rearrangement without somatic hypermutation. In PBL, MYC-IgH translocation and other MYC rearrangements are found in about 50%. It is characterized by p53 mutation (about 33%) and absence of BCL6 expression. These genetic profiles are important in determining the pathogenesis, prognosis, and treatment response of each lymphoma type.


4. General epidemiology

The annual incidence of AIDS-related NHL has fallen greatly, from about 50-100/100,000 persons with HIV before ART to about 5-15/100,000 after ART. DLBCL is the most common, at about 40% of AIDS-related NHL, followed by Burkitt lymphoma (about 30%), PCNSL (about 20%), PEL (about 3-4%), and PBL (about 2-3%). The incidence of PEL and PCNSL decreased the most after ART, whereas the incidence of Burkitt lymphoma and some high-grade NHL did not change much even after ART. In Korea, systematic epidemiologic data on AIDS-related NHL are limited, but cases are being reported with the increase in persons with HIV in Korea, and most are diagnosed as DLBCL in adults.


5. Pathophysiology

Chronic immune activation caused by HIV is the key background for B-cell hyperproliferation and tumorigenesis. The HIV gp120, Tat, and Nef proteins interact with B-cell surface receptors or create a cytokine environment (overexpression of IL-6, IL-10, IL-4), inducing B-cell hyperactivation and abnormal proliferation. In DLBCL, IL-10 and IL-6 act as autocrine growth signals for tumor cells, and BCL6 expression sustains the germinal center reaction, raising the risk of somatic hypermutation and chromosomal translocation. The EBV LMP1 protein activates the NF-κB pathway similarly to CD40 ligand, inducing anti-apoptosis and proliferation of B cells. In PEL, HHV-8 latency proteins (LANA, vFLIP, vCyclin) maintain the cell clone within the effusion cavity through promotion of cell proliferation, anti-apoptosis, and immune evasion. In PBL, EBV EBER and LMP1 promote differentiation toward plasma cells, and when a MYC translocation occurs, explosive cell proliferation takes place.


6. Symptoms

The clinical symptoms of AIDS-related NHL (B21.2) are characterized by very common extranodal involvement. Compared with DLBCL in the general population, extranodal involvement is higher in HIV-associated DLBCL, at about 60-70%, and occurs in various sites such as the gastrointestinal tract, bone marrow, liver, lung, and skin. B symptoms (fever, night sweats, weight loss of 10% or more within 6 months) accompany in about 50-80%. PCNSL: headache, altered consciousness, focal neurologic deficits, seizures. Progression is rapid, and neurologic deterioration can advance within days to weeks. PEL: pleural effusion (dyspnea, chest pain), ascites (abdominal distension, abdominal pain), pericardial effusion (shortness of breath, chest pain). A distinctive clinical pattern without formation of a solid mass. PBL: rapidly growing mass in the oral cavity or oropharynx, dysphagia, pain. Extranodal presentation is characteristic, and involvement of the digestive tract, paranasal sinuses, and skin is also possible.


7. Signs

Lymphadenopathy (firm and painless), hepatomegaly and splenomegaly, pleural effusion and ascites (PEL), neurologic abnormalities (PCNSL), and oral and oropharyngeal mass (PBL) appear according to type. Laboratory findings include markedly elevated LDH, elevated β2-microglobulin, anemia, thrombocytopenia (with bone marrow involvement), and hypoalbuminemia. In PCNSL, single or multiple ring-enhancing lesions on brain MRI are characteristic and must be differentiated from toxoplasma encephalitis. Elevated blood EBV DNA levels are used as an adjunct diagnostic indicator for EBV-associated lymphoma (especially PCNSL).


8. Screening

In persons with HIV, rapidly growing lymphadenopathy, unexplained pleural effusion, ascites, or pericardial effusion (suspected PEL), headache or neurologic abnormalities (suspected PCNSL), oral mass (suspected PBL), sudden rise in LDH, fever, and weight loss require immediate differentiation of lymphoma. At regular HIV visits, palpation of systemic lymph nodes and testing including LDH are recommended. In patients with CD4 <50/μL, new headache or neurologic symptoms should be evaluated with PCNSL as the first consideration.


9. Diagnosis

For all types, confirmation is pathologic diagnosis by tissue biopsy or cytology. Diagnosis of DLBCL: diffuse proliferation of large atypical B cells on tissue biopsy, immunophenotype (CD20+, CD19+, CD79a+), FISH (BCL6, BCL2, MYC). Diagnosis of PEL: cytospin smear of pleural/ascitic/pericardial fluid + immunocytochemistry (CD45+, CD30+, CD138±, CD20-, HHV-8 LANA-1 positive). Diagnosis of PBL: tissue biopsy (CD20-, CD138+, VS38c+, MUM1+, confirmation of MYC rearrangement). Diagnosis of PCNSL: brain MRI (+ contrast enhancement), CSF cell flow cytometry and EBV PCR, brain biopsy (essential for enhancing brain lesions with no response to empirical toxoplasma treatment). Systemic staging: PET-CT, bone marrow biopsy.


10. Treatment

DLBCL: 6 cycles of R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) is standard. SC-EPOCH-R has been widely adopted based on study results showing lower toxicity and similar efficacy in patients with HIV. At CD4 <100/μL, PCP prophylaxis (TMP-SMX) and G-CSF are given together to minimize bone marrow toxicity. PEL: No established standard regimen. CHOP or EPOCH chemotherapy. In some cases, anti-HHV-8 antiviral therapy (ganciclovir or cidofovir) is combined with chemotherapy. New regimens including bortezomib are in clinical trials. PBL: EPOCH, CODOX-M/IVAC, or CHOP. More intensive therapy is applied when MYC rearrangement is present. PCNSL: Methotrexate-based systemic chemotherapy (high-dose methotrexate 3.5 g/m² or more) ± rituximab. After CD4 recovery with ART, some PCNSL cases can achieve complete remission with chemotherapy alone, without radiation therapy. In all types, initiate/optimize ART early and manage drug interactions.


11. Prognosis

The prognosis of AIDS-related NHL (B21.2) differs greatly by type. DLBCL: in the era of ART + R-CHOP, complete remission rate about 50-70%, 5-year overall survival rate about 40-60%. Prognosis is good with CD4 >100/μL, good performance status, and stage I/II. PEL: very poor, with a median survival of about 3-6 months despite treatment. Even after ART + chemotherapy, the 1-year survival rate is only about 30-40%. PBL: poor, with a 1-year survival rate of about 30-40%. Worse if MYC rearrangement is positive. PCNSL: with ART + high-dose methotrexate therapy, median survival has improved from 1-2 months in the pre-ART era to 12-36 months, but remains poor. Overall, CD4 recovery is the most important prognostic determinant, and when immune recovery is achieved with ART, treatment-related toxicity also decreases and the complete remission rate improves.


12. Prevention

Maintaining CD4 through ART is the most effective way to prevent AIDS-related NHL overall, especially the immune-dependent DLBCL and PCNSL. Prophylactic antiviral therapy against EBV and HHV-8 is not yet clinically established. There is a suggestion that regular monitoring of EBV DNA and HHV-8 DNA in persons with HIV may help early detection of lymphoproliferative disease in high-risk groups (severe immunosuppression), but this is not a standard guideline. Early HIV diagnosis and ART initiation are the key public health strategy for NHL prevention.


13. References

  1. Carbone A, Vaccher E, Gloghini A. Hematologic cancers in individuals infected by HIV. Blood. 2016;128(8):1029-1041. DOI: 10.1182/blood-2016-04-712745. PMID: 27418640.

  2. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251-3262. DOI: 10.1182/blood-2013-04-498964. PMID: 24029446.

  3. Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013;105(16):1221-1229. DOI: 10.1093/jnci/djt158. PMID: 23833049.

  4. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186-1191. DOI: 10.1056/NEJM199505043321802. PMID: 7700311.

  5. Bibas M, Antinori A. EBV and HIV-related lymphoma. Mediterr J Hematol Infect Dis. 2009;1(2):e2009032. DOI: 10.4084/MJHID.2009.032. PMC: PMC3033167.

  6. Dunleavy K, Wilson WH. Appropriate staging and response assessment of lymphoma. Curr Opin Oncol. 2010;22(5):430-435. DOI: 10.1097/CCO.0b013e32833c443c. PMID: 20616653.

  7. Olszewski AJ, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016;30(5):787-796. DOI: 10.1097/QAD.0000000000000985. PMID: 26684818.

  8. Noy A, Lee JY, Cesarman E, et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126(2):160-166. DOI: 10.1182/blood-2015-02-629279. PMID: 25999451.

  9. Gérard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS. 2003;17(1):81-87. DOI: 10.1097/00002030-200301030-00011. PMID: 12478073.

  10. WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Haematolymphoid Tumours (5th ed.). IARC Press. 2022. ISBN: 9789283245049.